AAAAAA

   
Results: 1-25 | 26-27
Results: 1-25/27
IDENTIFICATION AND CHARACTERIZATION OF M4 SELECTIVE MUSCARINIC ANTAGONISTS
Authors: AUGELLISZAFRAN CE JAEN JC MORELAND DW NELSON CB PENVOSEYI JR SCHWARZ RD
Citation: Ce. Augelliszafran et al., IDENTIFICATION AND CHARACTERIZATION OF M4 SELECTIVE MUSCARINIC ANTAGONISTS, Bioorganic & medicinal chemistry letters, 8(15), 1998, pp. 1991-1996
TRACE LINES FOR CLASSIFICATION DECISIONS
Authors: SCHWARZ RD
Citation: Rd. Schwarz, TRACE LINES FOR CLASSIFICATION DECISIONS, Applied measurement in education, 11(4), 1998, pp. 311-330
DIFFERENTIAL EXPRESSION OF GROUP-I METABOTROPIC GLUTAMATE RECEPTORS (MGLURS) IN THE RAT PHEOCHROMOCYTOMA CELL-LINE PC12 - ROLE OF NERVE GROWTH-FACTOR AND RAS
Authors: KANE MD VANDENHEUVEL JP ISOM GE SCHWARZ RD
Citation: Md. Kane et al., DIFFERENTIAL EXPRESSION OF GROUP-I METABOTROPIC GLUTAMATE RECEPTORS (MGLURS) IN THE RAT PHEOCHROMOCYTOMA CELL-LINE PC12 - ROLE OF NERVE GROWTH-FACTOR AND RAS, Neuroscience letters, 252(1), 1998, pp. 1-4
DESIGN AND SYNTHESIS OF M1-SELECTIVE MUSCARINIC AGONISTS - (R)-(-)-(Z)-1-AZABICYCLO[2.2.1]HEPTAN-3-ONE, O-(3-(3'-METHOXYPHENYL)-2-PROPYNYL)OXIME MALEATE (CI-1017), A FUNCTIONALLY M1-SELECTIVE MUSCARINIC AGONIST
Authors: TECLE H BARRETT SD LAUFFER DJ AUGELLISZAFRAN C BRANN MR CALLAHAN MJ CAPRATHE BW DAVIS RE DOYLE PD EUBANKS D LIPINISKI W MIRZADEGAN T MOOS WH MORELAND DW NELSON CB PAVIA MR RABY C SCHWARZ RD SPENCER CJ THOMAS AJ JAEN JC
Citation: H. Tecle et al., DESIGN AND SYNTHESIS OF M1-SELECTIVE MUSCARINIC AGONISTS - (R)-(-)-(Z)-1-AZABICYCLO[2.2.1]HEPTAN-3-ONE, O-(3-(3'-METHOXYPHENYL)-2-PROPYNYL)OXIME MALEATE (CI-1017), A FUNCTIONALLY M1-SELECTIVE MUSCARINIC AGONIST, Journal of medicinal chemistry, 41(14), 1998, pp. 2524-2536
CALIBRATION AND SCORING OF TESTS WITH MULTIPLE-CHOICE AND CONSTRUCTED-RESPONSE ITEM TYPES
Authors: ERCIKAN K SCHWARZ RD JULIAN MW BURKET GR WEBER MM LINK V
Citation: K. Ercikan et al., CALIBRATION AND SCORING OF TESTS WITH MULTIPLE-CHOICE AND CONSTRUCTED-RESPONSE ITEM TYPES, Journal of educational measurement, 35(2), 1998, pp. 137-154
DEVELOPMENT OF M-1 SUBTYPE-SELECTIVE MUSCARINIC AGONISTS FOR ALZHEIMERS-DISEASE - TRANSLATION OF IN-VITRO SELECTIVITY INTO IN-VIVO EFFICACY
Authors: SCHWARZ RD CALLAHAN MJ DAVIS RE JAEN JC TECLE H
Citation: Rd. Schwarz et al., DEVELOPMENT OF M-1 SUBTYPE-SELECTIVE MUSCARINIC AGONISTS FOR ALZHEIMERS-DISEASE - TRANSLATION OF IN-VITRO SELECTIVITY INTO IN-VIVO EFFICACY, Drug development research, 40(2), 1997, pp. 133-143
PD102807 - A NOVEL M-4-SELECTIVE MUSCARINIC ANTAGONIST
Authors: GROSS J AUGELLISZAFRAN CE CZECHE S FRIEBE T JAEN JC PENVOSEYI JR SCHWARZ RD MUTSCHLER E LAMBRECHT G
Citation: J. Gross et al., PD102807 - A NOVEL M-4-SELECTIVE MUSCARINIC ANTAGONIST, Naunyn-Schmiedeberg's archives of pharmacology, 355(4), 1997, pp. 62-62
PHARMACOLOGICAL CHARACTERIZATION OF PD182807 - AN M4 SUBTYPE-SELECTIVE MUSCARINIC ANTAGONIST
Authors: SCHWARZ RD NELSON CB AUGELLISZAFRAN CE PENVOSE JR JAEN JC WILEY J FREY KA
Citation: Rd. Schwarz et al., PHARMACOLOGICAL CHARACTERIZATION OF PD182807 - AN M4 SUBTYPE-SELECTIVE MUSCARINIC ANTAGONIST, Life sciences, 60(13-14), 1997, pp. 10-10
IDENTIFICATION AND CHARACTERIZATION OF M4 SELECTIVE MUSCARINIC ANTAGONISTS
Authors: AUGELLISZAFRAN CE MORELAND DW NELSON CB PENVOSEYI JR SCHWARZ RD JEAN JC
Citation: Ce. Augelliszafran et al., IDENTIFICATION AND CHARACTERIZATION OF M4 SELECTIVE MUSCARINIC ANTAGONISTS, Life sciences, 60(13-14), 1997, pp. 11-11
FUNCTIONAL-CHARACTERIZATION OF PD102807 - A NOVEL M(4)-SELECTIVE MUSCARINIC ANTAGONIST
Authors: GROSS J AUGELLISZAFRAN CE CZECHE S FRIEBE T JAEN JC PENVOSEYI JR SCHWARZ RD MUTSCHLER E LAMBRECHT G
Citation: J. Gross et al., FUNCTIONAL-CHARACTERIZATION OF PD102807 - A NOVEL M(4)-SELECTIVE MUSCARINIC ANTAGONIST, Life sciences, 60(13-14), 1997, pp. 12-12
ACUTE EPIDIDYMITIS IN BOYS - ARE ANTIBIOTICS INDICATED
Authors: LAU P ANDERSON PA GIACOMANTONIO JM SCHWARZ RD
Citation: P. Lau et al., ACUTE EPIDIDYMITIS IN BOYS - ARE ANTIBIOTICS INDICATED, British Journal of Urology, 79(5), 1997, pp. 797-800
A STRUCTURE-ACTIVITY RELATIONSHIP STUDY OF NOVEL PHENYLACETAMIDES WHICH ARE SODIUM-CHANNEL BLOCKERS
Authors: ROUFOS I HAYS S SCHWARZ RD
Citation: I. Roufos et al., A STRUCTURE-ACTIVITY RELATIONSHIP STUDY OF NOVEL PHENYLACETAMIDES WHICH ARE SODIUM-CHANNEL BLOCKERS, Journal of medicinal chemistry, 39(7), 1996, pp. 1514-1520
Z-(+ -)-1-AZABICYCLO [2.2.1]HEPTAN-3-ONE, O-(3-ARYL-2-PROPYNYL) OXIMES AS POTENTIAL M1-SUBTYPE SELECTIVE MUSCARINIC AGONISTS/
Authors: TECLE H JAEN JC AUGELLISZAFRAN C BARRETT SD CAPRATHE BW LAUFFER DJ MIRZADEGAN T MOOS WH MORELAND DW PAVIA MR SCHWARZ RD THOMAS AJ DAVIS RE
Citation: H. Tecle et al., Z-(+ -)-1-AZABICYCLO [2.2.1]HEPTAN-3-ONE, O-(3-ARYL-2-PROPYNYL) OXIMES AS POTENTIAL M1-SUBTYPE SELECTIVE MUSCARINIC AGONISTS/, Bioorganic & medicinal chemistry letters, 5(6), 1995, pp. 631-636
(+ -)-1-AZABICYCLO[2.2.1]HEPTAN-3-ONE, O-(3-METHYL-5-ARYL-2-PENTEN-4-YNYL) OXIMES - POTENT MUSCARINIC AGONISTS/
Authors: TECLE H LAUFFER DJ DAVIS RE MIRZADEGAN T MORELAND DW SCHWARZ RD THOMAS AJ RABY C EUBANKS D BRANN MR JAEN JC
Citation: H. Tecle et al., (+ -)-1-AZABICYCLO[2.2.1]HEPTAN-3-ONE, O-(3-METHYL-5-ARYL-2-PENTEN-4-YNYL) OXIMES - POTENT MUSCARINIC AGONISTS/, Bioorganic & medicinal chemistry letters, 5(6), 1995, pp. 637-642
PRECLINICAL AND PHASE-1 CLINICAL CHARACTERIZATION OF CI-979 RU35926, A NOVEL MUSCARINIC AGONIST FOR THE TREATMENT OF ALZHEIMERS-DISEASE/
Authors: SEDMAN AJ BOCKBRADER H SCHWARZ RD
Citation: Aj. Sedman et al., PRECLINICAL AND PHASE-1 CLINICAL CHARACTERIZATION OF CI-979 RU35926, A NOVEL MUSCARINIC AGONIST FOR THE TREATMENT OF ALZHEIMERS-DISEASE/, Life sciences, 56(11-12), 1995, pp. 877-882
MUTATIONS OF ASPARTATE-103 IN THE HM2 RECEPTOR AND ALTERATIONS IN RECEPTOR-BINDING PROPERTIES OF MUSCARINIC AGONISTS
Authors: SCHWARZ RD SPENCER CJ JAEN JC MIRZADEGAN T MORELAND D TECLE H THOMAS AJ
Citation: Rd. Schwarz et al., MUTATIONS OF ASPARTATE-103 IN THE HM2 RECEPTOR AND ALTERATIONS IN RECEPTOR-BINDING PROPERTIES OF MUSCARINIC AGONISTS, Life sciences, 56(11-12), 1995, pp. 923-929
ARYLENEYNE 1-AZABICYCLO[2.2.1]HEPTAN-3-ONE OXIMES - POTENT MUSCARINICAGONISTS
Authors: TECLE H LAUFFER DJ DAVIS RE MIRZADEGAN T MORELAND DW SCHWARZ RD THOMAS AJ RABY C JAEN JC
Citation: H. Tecle et al., ARYLENEYNE 1-AZABICYCLO[2.2.1]HEPTAN-3-ONE OXIMES - POTENT MUSCARINICAGONISTS, Life sciences, 56(11-12), 1995, pp. 1003-1003
PHARMACOLOGICAL CHARACTERIZATION OF PD150714 - AN M1 SELECTIVE MUSCARINIC ANTAGONIST
Authors: NELSON CB AUGELLISZAFRAN CE CALLAHAN MJ CHRISTOFFERSEN C JAEN JC MELTZER LT PENVOSE JR SCHWARZ RD THOMAS AJ WILEY J
Citation: Cb. Nelson et al., PHARMACOLOGICAL CHARACTERIZATION OF PD150714 - AN M1 SELECTIVE MUSCARINIC ANTAGONIST, Life sciences, 56(11-12), 1995, pp. 1017-1017
IDENTIFICATION AND CHARACTERIZATION OF M1 SELECTIVE MUSCARINIC ANTAGONISTS
Authors: AUGELLISZAFRAN CE BLANKLEY CJ JAEN JC MORELAND DW NELSON CB PENVOSE JR SCHWARZ RD THOMAS AJ
Citation: Ce. Augelliszafran et al., IDENTIFICATION AND CHARACTERIZATION OF M1 SELECTIVE MUSCARINIC ANTAGONISTS, Life sciences, 56(11-12), 1995, pp. 1017-1017
EFFECT OF MUTATING ASPARTATE-103 TO GLUTAMATE OR ASPARAGINE IN THE HM2 SUBTYPE ON FINDING OF AGONISTS AND ANTAGONISTS OF VARIED PK(A) AND SUBTYPE SELECTIVITY
Authors: SPENCER CJ SCHWARZ RD MORELAND DW THOMAS AJ TECLE H
Citation: Cj. Spencer et al., EFFECT OF MUTATING ASPARTATE-103 TO GLUTAMATE OR ASPARAGINE IN THE HM2 SUBTYPE ON FINDING OF AGONISTS AND ANTAGONISTS OF VARIED PK(A) AND SUBTYPE SELECTIVITY, Life sciences, 56(11-12), 1995, pp. 1020-1020
AUTORADIOGRAPHIC DISTINCTION OF HIGH AND LOW-AFFINITY MUSCARINIC RECEPTORS BY THE M1-SELECTIVE LIGAND PD150714
Authors: FREY KA DESMOND T AUGELLISZAFRAN CE JAEN J SCHWARZ RD
Citation: Ka. Frey et al., AUTORADIOGRAPHIC DISTINCTION OF HIGH AND LOW-AFFINITY MUSCARINIC RECEPTORS BY THE M1-SELECTIVE LIGAND PD150714, Life sciences, 56(11-12), 1995, pp. 1036-1036
SYNTHESIS OF -METHYL-6-NITROPYRIDO[3,4-F]-QUINOXALINE-2,3-DIONE AND RELATED QUINOXALINEDIONES - CHARACTERIZATION OF LPHA-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID (AND N-METHYL-D-ASPARTATE) RECEPTOR AND ANTICONVULSANT ACTIVITY
Authors: BIGGE CF MALONE TC BOXER PA NELSON CB ORTWINE DF SCHELKUN RM RETZ DM LESCOSKY LJ BOROSKY SA VARTANIAN MG SCHWARZ RD CAMPBELL GW ROBICHAUD LJ WATJEN F
Citation: Cf. Bigge et al., SYNTHESIS OF -METHYL-6-NITROPYRIDO[3,4-F]-QUINOXALINE-2,3-DIONE AND RELATED QUINOXALINEDIONES - CHARACTERIZATION OF LPHA-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID (AND N-METHYL-D-ASPARTATE) RECEPTOR AND ANTICONVULSANT ACTIVITY, Journal of medicinal chemistry, 38(19), 1995, pp. 3720-3740
PD 142676 (CI 1002), A NOVEL ANTICHOLINESTERASE AND MUSCARINIC ANTAGONIST
Authors: EMMERLING MR GREGOR VE SCHWARZ RD SCHOLTEN JD CALLAHAN MJ LEE C MOORE CJ RABY C LIPINSKI WJ DAVIS RE
Citation: Mr. Emmerling et al., PD 142676 (CI 1002), A NOVEL ANTICHOLINESTERASE AND MUSCARINIC ANTAGONIST, Molecular neurobiology, 9(1-3), 1994, pp. 93-106
CIRCUMCISION QUESTIONS
Authors: ANDERSON PA SCHWARZ RD
Citation: Pa. Anderson et Rd. Schwarz, CIRCUMCISION QUESTIONS, Pediatrics, 94(3), 1994, pp. 407-407
SUBSTITUTED 2-BENZOTHIAZOLAMINE AS SODIUM FLUX INHIBITORS - QUANTITATIVE STRUCTURE-ACTIVITY-RELATIONSHIPS AND ANTICONVULSANT ACTIVITY
Authors: HAYS SJ RICE MJ ORTWINE DF JOHNSON G SCHWARZ RD BOYD DK COPELAND LF VARTANIAN MG BOXER PA
Citation: Sj. Hays et al., SUBSTITUTED 2-BENZOTHIAZOLAMINE AS SODIUM FLUX INHIBITORS - QUANTITATIVE STRUCTURE-ACTIVITY-RELATIONSHIPS AND ANTICONVULSANT ACTIVITY, Journal of pharmaceutical sciences, 83(10), 1994, pp. 1425-1432
Risultati: 1-25 | 26-27